Gilyazova, Irina,
Ivanova, Elizaveta,
Sinelnikov, Mikhail,
Pavlov, Valentin,
Khusnutdinova, Elza,
Khusnutdinova, Elza,
Beilerli, Aferin,
Mikhaleva, Ludmila,
Liang, Yanchao (2023) to explore the expression and possible
molecular mechanisms of the miR-153 action. Methods: Formalin
Gilyazova, I.,
Ivanova, E.,
Pavlov, V.,
Khasanova, G.,
Khasanova, A.,
Izmailov, A.,
Asadullina, D.,
Gilyazova, G.,
Wang, G.,
Gareev, I.,
Beylerli, O. (2023) with complications included 84 patients. Blood samples from patients
with HFRS for
molecular genetic analysis were
activity:
low (LMA), average (AMA) and high (HMA). SatO2, pO2, pCO2, p50 and HbO2were analyzed in capillary
Akhatov, I.Sh.,
Bikmeyev, A.T.,
Bilyalov, A.R.,
Chugunov, S.S.,
Galautdinov, M.F.,
Kireev, V.N.,
Kzhyshkowska, J.G.,
Pavlov, V.N.,
Pyatnitskaya, S.V.,
Yurovskikh, R.S. (2023) of such stages is the sintering, which means consolidation of a part blank with
low density to a dense final part
) and ischemic stroke (IS). Numerous studies have confirmed the importance of understanding the
molecularSufianov, Albert,
Begliarzade, Sema,
Beilerli, Aferin,
Liang, Yanchao,
Ilyasova, Tatiana,
Beylerli, Ozal (2023) and treatment of lung cancer remains grim, and effective therapeutic targets and
molecular markers are urgently
Khaliullin, F.A.,
Klen, E.E.,
Nikitina, I.L.,
Pavlov, V.N.,
Rozit, G.A.,
Gaisina, G.G.,
Samorodov, A.V. (2023) IXa is a
low-toxic substance (class 4 toxicity) with a high bioavailability predicted according
Chu, Shuk Han,
Zhao, Xu,
Komber, Ahmad,
Cheyne, Joshua,
Wu, Simiao,
Cowey, Eileen,
Kutlubaev, Mansur,
Mead, Gillian (2023) . Beneficial effects were seen in trials with
low risk of bias on randomization, missing outcome data